Caris Life Sciences publishes Assure liquid biopsy platform study

Caris Life Sciences (CAI) announced a study published in Scientific Reports, a Nature journal, demonstrating the utility of the Caris Assure blood-based biopsy assay across the cancer continuum. The Caris Assure liquid biopsy platform, powered by the Assure Blood-based Cancer Detection AI, was trained on over 376,000 whole exome and whole transcriptome tissue profiles and over 7,000 matched blood and tissue samples. Caris Assure : achieved sensitivities of 83.1% to 95.7% across cancer stages I-IV at 99.6% specificity; accurately identified the diagnostic pathway for MCED-positive cancers using the ABCDai-GPS model and demonstrated significant predictive power for recurrence, with hazard ratios of 33.4 for MRD and 4.39 for therapeutic monitoring.